Cargando…
iRhom2 in the pathogenesis of oral squamous cell carcinoma
iRhom2 is an inactive rhomboid protease involved in diverse signalling events. It has been implicated in the pathogenesis of a number of cancer types, including oesophageal and ovarian cancer, while its closely associated family member, iRhom1, is implicated in head and neck cancer. However, a role...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239832/ https://www.ncbi.nlm.nih.gov/pubmed/32236893 http://dx.doi.org/10.1007/s11033-020-05381-y |
_version_ | 1783536758944694272 |
---|---|
author | Agwae, Matthew E. Shaw, Richard J. Triantafyllou, Asterios Greaney, Frances S. T. Ben Salah, Khaled Risk, Janet M. |
author_facet | Agwae, Matthew E. Shaw, Richard J. Triantafyllou, Asterios Greaney, Frances S. T. Ben Salah, Khaled Risk, Janet M. |
author_sort | Agwae, Matthew E. |
collection | PubMed |
description | iRhom2 is an inactive rhomboid protease involved in diverse signalling events. It has been implicated in the pathogenesis of a number of cancer types, including oesophageal and ovarian cancer, while its closely associated family member, iRhom1, is implicated in head and neck cancer. However, a role for iRhom2 in head and neck cancer has not been investigated. Immunoblotting for iRhom2 in 54 oral squamous cell carcinoma (OSCC) and 24 paired normal tissues demonstrated higher levels of iRhom2 protein in tumour compared with normal samples (P < 0.05). iRhom2 over-expression correlated with poor patient survival (P < 0.0005) but with no other clinicopathological variable. Increased cell migration was observed in stably over-expressing iRhom2 clones of OSCC cell lines in the absence of increased cell proliferation, but not in the normal oral keratinocyte cell line, NOK-hTERT, and this was abrogated by knock-down of iRhom2. iRhom2 protein expression is increased in a proportion of OSCC and this up-regulation is associated with faster cell migration and decreased patient survival. These data implicate iRhom2-controlled signalling events in the pathogenesis of this cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11033-020-05381-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7239832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-72398322020-05-27 iRhom2 in the pathogenesis of oral squamous cell carcinoma Agwae, Matthew E. Shaw, Richard J. Triantafyllou, Asterios Greaney, Frances S. T. Ben Salah, Khaled Risk, Janet M. Mol Biol Rep Short Communication iRhom2 is an inactive rhomboid protease involved in diverse signalling events. It has been implicated in the pathogenesis of a number of cancer types, including oesophageal and ovarian cancer, while its closely associated family member, iRhom1, is implicated in head and neck cancer. However, a role for iRhom2 in head and neck cancer has not been investigated. Immunoblotting for iRhom2 in 54 oral squamous cell carcinoma (OSCC) and 24 paired normal tissues demonstrated higher levels of iRhom2 protein in tumour compared with normal samples (P < 0.05). iRhom2 over-expression correlated with poor patient survival (P < 0.0005) but with no other clinicopathological variable. Increased cell migration was observed in stably over-expressing iRhom2 clones of OSCC cell lines in the absence of increased cell proliferation, but not in the normal oral keratinocyte cell line, NOK-hTERT, and this was abrogated by knock-down of iRhom2. iRhom2 protein expression is increased in a proportion of OSCC and this up-regulation is associated with faster cell migration and decreased patient survival. These data implicate iRhom2-controlled signalling events in the pathogenesis of this cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11033-020-05381-y) contains supplementary material, which is available to authorized users. Springer Netherlands 2020-03-31 2020 /pmc/articles/PMC7239832/ /pubmed/32236893 http://dx.doi.org/10.1007/s11033-020-05381-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Short Communication Agwae, Matthew E. Shaw, Richard J. Triantafyllou, Asterios Greaney, Frances S. T. Ben Salah, Khaled Risk, Janet M. iRhom2 in the pathogenesis of oral squamous cell carcinoma |
title | iRhom2 in the pathogenesis of oral squamous cell carcinoma |
title_full | iRhom2 in the pathogenesis of oral squamous cell carcinoma |
title_fullStr | iRhom2 in the pathogenesis of oral squamous cell carcinoma |
title_full_unstemmed | iRhom2 in the pathogenesis of oral squamous cell carcinoma |
title_short | iRhom2 in the pathogenesis of oral squamous cell carcinoma |
title_sort | irhom2 in the pathogenesis of oral squamous cell carcinoma |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239832/ https://www.ncbi.nlm.nih.gov/pubmed/32236893 http://dx.doi.org/10.1007/s11033-020-05381-y |
work_keys_str_mv | AT agwaematthewe irhom2inthepathogenesisoforalsquamouscellcarcinoma AT shawrichardj irhom2inthepathogenesisoforalsquamouscellcarcinoma AT triantafyllouasterios irhom2inthepathogenesisoforalsquamouscellcarcinoma AT greaneyfrancesst irhom2inthepathogenesisoforalsquamouscellcarcinoma AT bensalahkhaled irhom2inthepathogenesisoforalsquamouscellcarcinoma AT riskjanetm irhom2inthepathogenesisoforalsquamouscellcarcinoma |